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S U M M A R Y
Mycobacterium africanum comprises two phylogenetic lineages within the Mycobacterium tuberculosis
complex (MTBC).M. africanumwas ﬁrst described and isolated in 1968 from the sputum of a Senegalese
patient with pulmonary tuberculosis (TB) and it has been identiﬁed increasingly as an important cause of
human TB, particularly prevalent inWest Africa. The restricted geographical distribution ofM. africanum,
in contrast to thewidespread global distribution of other species ofMTBC, requires explanation. Available
data indicate that M. africanum may also have important differences in transmission, pathogenesis, and
host–pathogen interactions, which could affect the evaluation of new TB intervention tools (diagnostics
and vaccines)–those currently in use and those under development. The unequal geographical
distribution and spread of MTBC species means that individual research ﬁndings from one country or
region cannot be generalized across the continent. Thus, generalizing data from previous and ongoing
research studies onMTBCmay be inaccurate and inappropriate. Amajor rethink is required regarding the
design and structure of future clinical trials of new interventions. The West, Central, East, and Southern
African EDCTP Networks of Excellence provide opportunities to take forward these pan-Africa studies.
More investments intomolecular, epidemiological, clinical, diagnostic, and immunological studies across
the African continent are required to enable further understanding of host–M. africanum interactions,
leading to the development of more speciﬁc diagnostics, biomarkers, host-directed therapies, and
vaccines for TB.
 2016 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).1. Introduction
Tuberculosis (TB) in humans is caused by one of several
genetically related groups of organisms comprising the* Corresponding author.
E-mail address: dyeboah-manu@noguchi.ug.edu.gh (D. Yeboah-Manu).
http://dx.doi.org/10.1016/j.ijid.2016.12.003
1201-9712/ 2016 The Author(s). Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Mycobacterium tuberculosis complex (MTBC). Genomic studies
indicate that all MTBC species have between 95% and 100% DNA
relatedness, with the same 16S rRNA.1,2 Mycobacterium tuberculo-
sis sensu stricto is responsible for a large proportion of human TB
cases worldwide.3 Other MTBC species that cause human
disease include Mycobacterium bovis, Mycobacterium africanum,
Mycobacteriummicroti,Mycobacterium canettii, andMycobacterium
pinnipedii.4–6 Globally, TB continues to be a major public healthciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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death. The World Health Organization annual TB report for
2016 states that there were 10 million cases of active TB in
2015, with an estimated 1.5 million associated deaths.7
Over the past six decades, the common dogma prevailing has
been that all members of the MTBC are genetically similar, with a
clonal population. Thus, it has generally been assumed that the
small genotypic or phenotypic differences do not translate into
differences in transmission, pathogenesis, host–pathogen interac-
tion, disease outcome, and efﬁcacy of diagnostics and vaccines. A
huge amount of resources and effort have been invested in
developing new TB diagnostics, TB drugs, treatment regimens, and
vaccines. Currently available diagnostics and vaccines, and those
under development, have been based on this assumption.
However, molecular and clinical studies combined with genomic
analyses have shown important strain diversity among the
differentmembers of theMTBC.4,8–12 Differences between lineages
could affect the performance of diagnostics, treatments, and
vaccines.
Available data obtained from epidemiological, clinical, and
immunological studies on M. africanum in West Africa are
highlighted in this viewpoint;10,13 these indicate important
differences in transmission, pathogenesis, and host–pathogen
interactions. The need for a radical rethink to improve current
understanding of host–pathogen interactions and for the develop-
ment and evaluation of new diagnostics, biomarkers, host-directed
therapies, and speciﬁc vaccines for TB is also discussed.
2. Geographical distribution of M. africanum
M. africanum was ﬁrst described and isolated in 1968 from the
sputum of a Senegalese patient with pulmonary TB.5 M. africanum
is made up of two lineages within the MTBC: MTBC lineage 5 (also
called M. africanum West African type I) and MTBC lineage 6 (M.
africanum West African type II).13,14 With advances in diagnostic
technologies, M. africanum has been identiﬁed increasingly as an
important cause of human TB, causing nearly 50% of all TB cases
reported in West Africa. The following country prevalence of M.
africanum has been reported: Benin 39%, Burkina Faso 18%,
Cameroon 56%, The Gambia 39%, Ghana 20%, Guinea Bissau 47%,
Ivory Coast 55%, Nigeria 8%, Senegal 20%, Sierra Leone 24%.13,15–
20 M. africanum has also been reported infrequently among TB
patients from across Europe, South America, and the USA.21–26 It is
assumed that TB caused byM. africanum in non-African countries is
due to human migration from disease-endemic West African
regions.
Recent advances in molecular technology have allowed studies
on the evolution of the nature of M. africanum genotypes, its
position within the MTBC, and its genotypic and phenotypic
expression, speciﬁc clade identiﬁcation, transmission patterns,
infectivity, and disease expression in humans.10–33 Whether there
are signiﬁcant differences between M. tuberculosis and M.
africanum in their clinical presentation, epidemiology, association
with migration, transmission patterns, pathogenesis, virulence,
rate of progression of disease, and treatment outcomes needs to be
deﬁned.
3. Clinical manifestations, transmission, and genotype studies
of TB due to M. africanum
Several small clinical cohort studies from West Africa have
evaluated differences in clinical presentation between TB caused
by M. africanum and TB caused by M. tuberculosis sensu stricto.10–
12,27–33 Aerosol spread and symptoms at presentation seem similar
in both. No signiﬁcant associations ofM. africanumwith HIV status
and chest X-ray changes have been noted. Contacts of patientswithM. africanum infection appear to have a lower rate of progression to
active TB compared with contacts of M. tuberculosis-infected
patients.34 A lower rate of genotype clustering for M. africanum
compared to M. tuberculosis has been reported.35 Other studies
have reported that M. africanum West African type II has a similar
rate of transmission as M. tuberculosis sensu stricto, although it
may be associated with a lower rate of progression to disease in
contacts.36,37
4. M. africanum genotype, immunological responses, and
diagnostic tests
Immunological studies reported from The Gambia have shown
marked differences in clinical features, immune response, gene
expression, and proteins associatedwith inﬂammation betweenM.
tuberculosis sensu stricto-infected patients and M. africanum-
infected patients .35,38,39 A number of genomic polymorphisms
unique to M. africanum in West Africa and a study using whole
genome sequencing of fourM. africanum isolates against H37Rv,11
have shown a number of frame-shifts and non-synonymous
mutations within some functional operons, including genes
associated with immunogenicity and host invasion. It was
highlighted that potential differential gene expression could have
implications for diagnostic tests and management algorithms in
West Africa, especially when these genes are being targeted for
diagnostic test purposes.
The gene product of mpt64 is the target of three widely used
rapid speciation lateral ﬂow assays for the identiﬁcation of the
MTBC in culture: BD MGIT TBc Identiﬁcation Test (BD TBc ID;
Becton Dickinson Diagnostics, Becton, Dickinson and Company,
Sparks, MD, USA); SD Bioline Ag MPT64 Rapid (SD Bioline;
Standard Diagnostics, Inc., Yongin-si, Gyeonggi-do, Republic of
Korea); and Capilia TB-Neo (TAUNS Laboratories, Inc., Numazu,
Shizuoka, Japan). Despite the advantage of lateral ﬂow assays,
there have been reports of the failure of MPT64 tests to detect
MTBC isolates, resulting in erroneous reporting of a non-
tuberculous mycobacteria (NTM) diagnosis. A systematic evalua-
tion of two commonly used rapid TB tests that detect the product
of the mycobacterialmpt64 gene compared the abundance of the
mpt64 gene product in sputum samples of patientswith untreated
pulmonary TB caused by M. africanum type II or M. tuberculosis
sensu stricto. Ofori-Anyinam et al. compared the expression of the
mpt64 gene in sputa from M. africanum and M. tuberculosis sensu
stricto-infected Gambian patients and found that thempt64 gene
was 2.5-fold less expressed inM. africanum than inM. tuberculosis
sensu stricto.33 Thus the sensitivity of rapid tests was 20% lower
for M. africanum cultures than for M. tuberculosis sensu stricto
cultures.33 A non-synonymous single nucleotide polymorphism
(SNP) in thempt64 gene of that lineage was identiﬁed. Thempt64
(Rv1980c) mRNA transcript was signiﬁcantly less abundant in the
sputa of TB patients infected with M. africanum type II compared
to patients infected with M. tuberculosis sensu stricto, suggesting
that the MPT64 protein may be produced at a slower rate. There
also appeared to be lineage-dependent and time-speciﬁc differ-
ences in conversion toMPT64 test positivity. Thus, inWest Africa,
tests to identify MTBC in culture miss a substantial fraction of
TB cases, and this may have direct consequences for the patients
and for TB control efforts. These data have important implications
for the performance of diagnostic tests and any new TB vaccine in
West Africa.
5. Bugbear of current portfolio of geographically restricted TB
research
Recent debates have focused onwhether the currently available
diagnostic tests are speciﬁc and reliable for all types of MTBC
A. Zumla et al. / International Journal of Infectious Diseases 56 (2017) 126–129128lineage, or whether treatment or vaccine success or failure will
be determined by the speciﬁc nature of MTBC lineages. Given the
limited efﬁcacy of the current TB vaccine and the recent clinical
failure of the most advanced new TB vaccine candidate, novel
concepts for vaccine design should be explored. Over the past
5 years, advances in molecular technologies have shown that
MTBC lineages differ in their phenotypes and that they may also
differ in their pathogenicity. Thus any generalizing of data from
previous and ongoing research studies on TB may be inappropri-
ate and inaccurate. The unequal geographical distribution and
spread of MTBC species across Africa means that individual
research ﬁndings from one country or region cannot be
generalized across the continent.13 Thus, a major rethink is
required for the design and structure of future clinical trials of
new diagnostic and preventive interventions. Phylogeographic
studies across the African continent are now required to improve
the design and interpretation of epidemiological research,
translational clinical research, and evaluation trials of new
interventions (rapid diagnostics, new drugs and treatment
regimens, and vaccines).
6. Conclusions and the way forward
Recent phylogenomic analysis of global strains has indicated
that while some lineages and sub-lineages casually referred to as
generalist can infect different populations, the majority of
tuberculous lineages and sub-lineages are ‘specialized’ to cause
TB disease in distinct human populations. M. africanum classiﬁed
into L5 and L6 seems to have specialized and remains an important
cause of TB in West Africa. With the wide spectrum of MTBC
lineages present across Africa, these patient cohorts provide ideal
trial sites for evaluation studies . Increased investment in the study
of M. africanum is required to further our understanding of MTBC
epidemiology, evolution, and pathogenesis. The diversitywithinM.
africanum must be factored into priority agendas of funders and
current investments into new TB biomarkers and vaccine
development. With the limited efﬁcacy of bacille Calmette–Gue´rin
(BCG) and the failure of the Oxford TB vaccine, novel concepts for
vaccine design should be explored, such as the highly variable T-
cell epitopes. Moreover, there is increasing evidence that the
human-adapted MTBC has been co-evolving with the human host
for a long time. Hence, studying the interaction between bacterial
and human genetic diversity might help identify additional targets
that could be exploited for TB vaccine development. It is important
that systematic collaborative research studies are also conducted
across Africa to determine the contribution of host genetics,
ethnicity, or other factors in the persistent circulation of M.
africanum in West Africa. Moreover, such studies also have the
potential to help in developing host-speciﬁc adjunct host-directed
therapies against both M. africanum and M. tuberculosis sensu
stricto.40 Whilst the infrastructure and resources for the perfor-
mance of these pan-African studies have been lacking, the second
European Developing Countries Clinical Trials Partnership pro-
gram (EDCTP2)41 and the EDCTP regional networks of excel-
lence42,43 now provide new opportunities to take forward these
important studies.
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